Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ngozika Orjioke

Pulmonary Disease East Point, GA Medical Doctor

NPI 1275754731 CMS profile 57437

1136 Cleveland Ave Ste 615, East Point, GA 30344

Open in the dashboard

General payments

$67,868

337 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$778,444 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Ngozika Orjioke of East Point, GA is reported in the CMS Open Payments database as having received $67,868 across 337 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $778,444 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,719 66
2024 General $17,741 68
2023 General $24,198 67
2022 General $14,273 66
2021 General $472 26
2020 General $1,116 23
2019 General $349 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ngozika Orjioke
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Ngozika Orjioke were reported at $9,719. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Ngozika Orjioke Pulmonary Disease median Middle half National median
2019 $349 $377 $109–$1,340 $163
2020 $1,116 $230 $56–$907 $114
2021 $472 $269 $68–$1,072 $132
2022 $14,273 $390 $100–$1,457 $149
2023 $24,198 $419 $114–$1,659 $160
2024 $17,741 $476 $123–$1,818 $164
2025 $9,719 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $60,015 69 payments
  2. Chiesi USA, Inc. $1,914 2 payments
  3. Mallinckrodt Hospital Products Inc. $947 37 payments
  4. Baxter Healthcare $898 43 payments
  5. Actelion Pharmaceuticals US, Inc. $782 39 payments
  6. Mylan Specialty L.P. $722 1 payment
  7. AstraZeneca Pharmaceuticals LP $551 18 payments
  8. ANI Pharmaceuticals, Inc. $451 46 payments
  9. GlaxoSmithKline, LLC. $404 23 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $224 12 payments
  11. Other $959 47 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $41,532 13 payments
  2. Travel and Lodging $10,839 25 payments
  3. Consulting Fee $8,800 2 payments
  4. Food and Beverage $6,307 292 payments
  5. Education $390 5 payments
Products named General payments · program years 2019–2025
  1. Veklury $56,112 53 payments
  2. ACTHAR $947 37 payments
  3. Hillrom - Life 2000 Ventilation System $754 35 payments
  4. Yupelri $722 1 payment
  5. OPSUMIT $515 26 payments
  6. UPTRAVI $505 21 payments
  7. PURIFIED CORTROPHIN GEL $417 44 payments
  8. TRELEGY ELLIPTA $192 10 payments
  9. FASENRA $171 9 payments
  10. Hillrom - Vest System Model 105 Home Care $122 6 payments
  11. Other $1,696 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

836

Median for Pulmonary Disease: 936

Drug cost

$275,337

Median for Pulmonary Disease: $487,987

Branded share of claims

81.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 201 $165,077
Breo Ellipta Fluticasone/Vilanterol Brand 54 $24,794
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 34 $15,240
Atrovent Hfa Ipratropium Bromide Brand 20 $12,105
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 25 $11,330
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 20 $9,467
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 13 $8,135
Albuterol Sulfate Hfa Albuterol Sulfate Brand 209 $6,898
Incruse Ellipta Umeclidinium Bromide Brand 14 $6,774
Symbicort Budesonide/Formoterol Fumarate Brand 17 $6,672

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$118,399

Medicare's payments for the services billed

Medicare patients

178

Average age 70

Services billed

1,072

99 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 57%
COPD 53%
Heart failure 49%
Chronic kidney disease 47%
Arthritis 37%
Ischemic heart disease 31%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veklury
  • Gilead Sciences, Inc. $16,547
$16,547 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $282
$282 — —
PURIFIED CORTROPHIN GEL
  • ANI Pharmaceuticals, Inc. $219
$219 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $73
$73 — —
WINREVAIR
  • Merck Sharp & Dohme Corporation $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

337 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record